Asia Pacific Pharmaceutical Science Summit Forum (APPSF)

I am writing on behalf of Indian Pharmaceutical Association (IPA). We would be pleased to welcome you as the speaker to attend Asia Pacific Pharmaceutical Science Summit Forum（APPSF）on Jan. 9-10, 2019 in Shanghai, China and give a 40-minute talk on: 1. New Drug Development Pathways in China 2. Generic Drugs: Research, Development and Regulatory Strategy Visions 3. Quality by Design -Concept and Implementation 4. Analytical Application and Biosimilar Introduction. We have watched your interview on the Internet and read your articles, and we would like to meet you and learn more about how you lead the pharmaceutical industry as well as the market to the road of innovation.

It is an honor and privilege to invite you to participate in our forum. We believe that your topic to pharmaceutics awareness is unparalleled, and are looking forward to hearing you speak on the forum. We will cover your expenses incurred during the conference for——travel and accommodation.

Thank you for considering our invitation. I hope to receive a positive reply from you before 11:59 p.m. on Nov. 9, 2018. If you have any questions, I can be reached anytime at yangchao@sjbmcc.com.

Kind regards,

Yours sincerely,

 Indian Pharmaceutical Association (IPA)

Organizing Committee of Asia Pacific Pharmaceutical Science Summit Forum（APPSF）

Time:           Jan. 9-10, 2019

Venue:          Sheraton Shanghai Hongkou Hotel

Host:           Indian Pharmaceutical Association (IPA)

                SHENGJIE(Shanghai) Business Management & Consulting Co., Ltd

Co-organizers:  Pharmacy Council of India (PCI)

Director:        Chamber of Informatic Industry Commerce, Shanghai Federation of Industry and Commerce (SFIC)

Supporters:     Health Branch of Shanghai Federation of Industry and Commerce

ACPI KSPOR

Acharya Institutes

JSS Academy of Higher Education & Research

Media Partners: People.com.cn, Xinhua Net, The Paper, Eastday, Tencent, DXY, PHARMCUBE, Yaozhi, PharmFuture etc.

Forum Introduction: Asia-pacific Alliance, To improve Health Care Industry!

Domestic pharmaceutical companies face serious challenges now.

Join APPSF for the next breakthrough.

On Innovate Drugs

The current size of Chinese anti-tumor market is about 140 billion yuan. One third of the market is covered by the imported drugs. Drugs with the best curative effect are mostly imported. Although China has become the second largest medical and pharmaceutical market in the world, its proportion of innovative drugs with independent intellectual property rights is only 18%, far below the level of the United States, Europe and Japan.

On Generic Drugs

The global generic drugs market was valued at around US$ 244.5 Billion in 2017, growing at a compound annual growth rate (CAGR) of around 8% during 2010-2017 and Is expected to reach approximately USD 380.60 billion by 2021, expected growing at a CAGR of around 10.8 % between 2016 and 2021. FDA’s 2018 Proposal to Harmonize Standards for Generic Drugs, with such initiatives from Global regulatory bodies, propels the future of producing generic drug and makes the Generic Drug industry a high potential market and reason for generating more revenue for generic drugs Pharmaceutical industry. Thus, the current conference focuses on providing information to understand current global regulatory requirement for generic drug development and making your success path easy for contribution for development of quality medicine and treatment in cost effective way.

On QbD

Quality by Design (QbD) continues to be a hot topic across the life science industries, and as evidenced by the widespread adoption of QbD among manufacturers, there is no question about its benefits.   As the pharma sector moves to implement pharmaceutical QbD, regulatory bodies such as the FDA work provide a common understanding of key concepts, terminology and expectations. This conference focuses on reviewing the current understanding of concepts of pharmaceutical QbD and its implementation.

On Biosimilar:

Biosimilars are often confused with generic drugs—but they are not the same. Unlike generics, the FDA requires a biosimilar to be highly similar, but not identical to the existing biologic medicine, which is referred to as a "reference product”. Biopharmaceuticals accounted for nearly 25% of the global pharmaceutical market revenues from marketed drugs (~$1,100 billion) in 2016. To add to this, the patent expiry of the leading 10 biologic drugs represents a massive $70 billion opportunity for pharma companies over the period 2015 - 2020. Please join APPSF to learn more about the future game changer – Biosimilar.

We look forward to having professionals from related industries worldwide to attend this Asia Pacific Pharmaceutical Science Summit Forum（APPSF）. With the industry insight and problem-oriented strategy, we will lead the pharmaceutical industry and market to the road of innovation. It would be great to have this forum in January. Let’s create and develop together.

Schedule

Agenda

More guest speakers are coming in, and the final schedule is subject to the actual arrangement of the conference.